Anteris Files S-1 for Resale, Eyes $40.4M from Warrants Amidst Pivotal Trial Launch

TL;DR

**AVR's S-1 for selling shareholder resales could create near-term price volatility, but the potential $40.4M from warrant exercises is a bullish signal for its pivotal DurAVR THV trial.**

AI Summary

Anteris Technologies Global Corp. (AVR) filed an S-1 on November 26, 2025, for the resale of up to 9,103,796 shares of common stock by selling stockholders. The company will not receive proceeds from these sales, but may receive up to approximately $40.4 million from warrant exercises. Anteris is a structural heart company focused on its DurAVR Transcatheter Heart Valve (THV) System for aortic stenosis, which has treated 130 patients as of September 2025. The company initiated its global pivotal PARADIGM Trial in October 2025 with European regulatory clearance in Denmark and received FDA approval for its Investigational Device Exemption in Q4 2025. Anteris completed its IPO on December 12, 2024, raising $80.0 million net proceeds from selling 14,878,481 shares at $6.00 per share. Despite being a development-stage company with recurring net operating losses, Anteris targets a TAVR market expected to reach $9.9 billion by 2028.

Why It Matters

This S-1 filing signals a potential increase in AVR's public float as selling stockholders prepare to offload nearly 9.1 million shares, which could exert downward pressure on the stock price. However, the potential for Anteris to receive up to $40.4 million from warrant exercises provides a crucial capital injection for its ongoing PARADIGM Trial, a critical step towards commercializing its DurAVR THV System. The company's focus on a biomimetic valve for aortic stenosis positions it in a competitive market against established TAVR players, with its success hinging on the trial's outcomes and market adoption of its 'all patients' solution.

Risk Assessment

Risk Level: medium — The company is a development-stage entity with recurring net operating losses since inception, indicating significant financial risk. While the potential $40.4 million from warrant exercises is positive, the resale of 9,103,796 shares by selling stockholders could dilute value and pressure the stock price, as the company will not receive proceeds from these sales.

Analyst Insight

Investors should monitor the volume and timing of selling stockholder sales to gauge potential downward pressure on AVR's stock. However, the capital infusion from warrant exercises and the progress of the PARADIGM Trial are key long-term catalysts, suggesting a 'wait and see' approach for new positions until trial data emerges.

Financial Highlights

debt To Equity

Not disclosed

revenue

$0

operating Margin

Negative value not disclosed

total Assets

Not disclosed

total Debt

Not disclosed

net Income

Negative value not disclosed

eps

Negative value not disclosed

gross Margin

Not disclosed

cash Position

Not disclosed

revenue Growth

N/A

Key Numbers

• 9,103,796 — Shares of Common Stock (Total shares registered for resale by selling stockholders)
• $40.4 million — Aggregate gross proceeds (Potential proceeds to Anteris upon exercise of warrants)
• $3.85 — Closing price per share (Closing price of AVR Common Stock on Nasdaq on November 25, 2025)
• 130 — Patients treated (Total patients treated with DurAVR THV worldwide as of September 2025)
• $80.0 million — Net proceeds (Received from initial public offering on December 12, 2024)
• 14,878,481 — Shares sold in IPO (Number of shares sold in the initial public offering at $6.00 per share)
• $9.9 billion — Global market opportunity (Projected total global market for TAVR in severe aortic stenosis by 2028)
• $2.5 billion — Global market opportunity (Projected total global market for ViV TAVR procedures by 2028)

Key Players & Entities

• Anteris Technologies Global Corp. (company) — Registrant and issuer of common stock
• Wayne Paterson (person) — Chief Executive Officer of Anteris Technologies Global Corp.
• Jones Day (company) — Legal counsel for Anteris Technologies Global Corp.
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• Nasdaq Global Market (company) — Stock exchange where AVR Common Stock is listed
• Australian Securities Exchange (company) — Stock exchange where AVR CDIs trade
• v2vmedtech, inc. (company) — Strategic investment and development partner
• U.S. Food and Drug Administration (regulator) — Approved TAVR and granted IDE approval for PARADIGM Trial

FAQ

Risk Factors

• Dependence on Future Financing [high — financial]: The company is a development-stage entity with a history of net operating losses and expects to incur significant expenses and operating losses for the foreseeable future. Anteris will require substantial additional capital to fund its operations, research and development, clinical trials, and commercialization efforts. Failure to secure adequate financing could impair its ability to continue as a going concern.
• Regulatory Approval Delays [high — regulatory]: The success of Anteris's DurAVR THV System is contingent upon obtaining and maintaining regulatory approvals, including FDA clearance and CE Mark. Delays or failures in obtaining these approvals for its pivotal PARADIGM Trial or commercialization can significantly impact market entry and revenue generation. The company received FDA approval for its Investigational Device Exemption in Q4 2025, but full market approval timelines are critical.
• Competition in TAVR Market [high — market]: The transcatheter aortic valve replacement (TAVR) market is highly competitive and rapidly evolving, with established players and emerging technologies. Anteris faces competition from companies with significant resources and existing market share. The projected $9.9 billion global market opportunity by 2028 is attractive but intensely contested.
• Manufacturing and Supply Chain Risks [medium — operational]: Anteris relies on third-party manufacturers for its DurAVR THV System. Any disruptions in its supply chain, quality control issues, or inability of manufacturers to scale production could adversely affect its ability to meet demand and commercialize its product.
• Potential Dilution from Warrant Exercises [medium — financial]: The S-1 filing registers 9,103,796 shares for resale by selling stockholders, and Anteris may receive up to $40.4 million from warrant exercises. While this provides potential capital, the exercise of these warrants could lead to significant dilution for existing shareholders if not managed strategically.
• Intellectual Property Disputes [medium — legal]: The medical device industry is characterized by extensive patent protection. Anteris's success depends on its ability to protect its intellectual property and avoid infringing on the patents of others. Litigation or disputes could be costly and disruptive.
• Limited Commercial Experience [medium — market]: As a development-stage company, Anteris has limited experience in commercializing medical devices. Building a sales force, establishing distribution channels, and gaining market acceptance for the DurAVR THV System will be challenging and require significant investment.
• Post-Market Surveillance Requirements [low — regulatory]: Following regulatory approval, Anteris will be subject to ongoing post-market surveillance, reporting requirements, and potential regulatory actions if its device fails to perform as expected or causes adverse events. This requires robust quality management systems.

Industry Context

Anteris Technologies operates in the rapidly growing structural heart market, specifically focusing on Transcatheter Aortic Valve Replacement (TAVR). This market is characterized by significant innovation and a projected global opportunity of $9.9 billion by 2028. However, it is also highly competitive, with established medical device giants and emerging players vying for market share. Key trends include the shift towards less invasive procedures and the development of next-generation devices with improved durability and patient outcomes.

Regulatory Implications

Anteris faces significant regulatory hurdles, primarily related to obtaining and maintaining approvals from bodies like the FDA and European authorities for its DurAVR THV System. The company's ability to successfully navigate clinical trials, such as the PARADIGM Trial, and meet stringent post-market surveillance requirements is critical. Any delays or failures in the regulatory process could severely impact its commercialization timeline and market access.

What Investors Should Do

1. Monitor progress of the PARADIGM Trial and FDA/CE Mark approval timelines.
2. Assess the company's ability to secure future financing.
3. Evaluate competitive positioning within the TAVR market.
4. Analyze the potential impact of warrant exercises on share dilution.
5. Review the clinical data and patient outcomes from the 130 patients treated with DurAVR THV.

Key Dates

• 2024-12-12: Completed Initial Public Offering (IPO) — Raised $80.0 million in net proceeds, providing capital for development and operations.
• 2025-09-30: DurAVR THV System treated 130 patients — Demonstrates early clinical adoption and real-world use of the company's core product.
• 2025-10-01: Initiated global pivotal PARADIGM Trial — Crucial step towards broader regulatory approval and market access for the DurAVR THV System.
• 2025-11-26: Filed S-1 for resale of shares by selling stockholders — Allows existing shareholders to sell shares and potentially provides liquidity, while also registering shares for potential warrant exercises.
• 2025-Q4: Received FDA approval for Investigational Device Exemption (IDE) — Enables the company to proceed with clinical trials in the U.S., a key market.
• 2025-11-25: AVR Common Stock closing price — Indicates current market valuation of the company at $3.85 per share.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and management. (This filing details the resale of shares and potential proceeds from warrant exercises, providing insight into shareholder liquidity and future capital generation.)

Transcatheter Heart Valve (THV)

A minimally invasive artificial heart valve that is delivered to the heart via a catheter, typically through a blood vessel in the leg or chest. (Anteris's core product, the DurAVR THV System, is a type of THV designed to treat aortic stenosis.)

Aortic Stenosis

A condition where the aortic valve of the heart narrows, restricting blood flow from the left ventricle to the aorta. (This is the primary condition that Anteris's DurAVR THV System is designed to treat.)

TAVR

Transcatheter Aortic Valve Replacement, a procedure using a THV to replace a diseased aortic valve. (Anteris operates within the TAVR market, which is projected to grow significantly.)

Warrant

A security that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price (the exercise price) within a certain timeframe. (Anteris may receive up to $40.4 million from the exercise of outstanding warrants, impacting its cash position.)

Investigational Device Exemption (IDE)

An approval from the FDA that allows a medical device to be studied in clinical trials in humans. (FDA IDE approval is a critical step for Anteris to conduct its PARADIGM Trial in the U.S.)

Pivotal Trial

A clinical trial designed to provide the primary evidence of a new medical treatment's safety and effectiveness for regulatory approval. (The PARADIGM Trial is Anteris's key study to gain market approval for its DurAVR THV System.)

Selling Stockholders

Existing shareholders who are registering their shares for resale to the public. (The S-1 filing pertains to the resale of shares by these stockholders, not the issuance of new shares by Anteris.)

Year-Over-Year Comparison

This S-1 filing focuses on the resale of shares by existing stockholders and potential proceeds from warrant exercises, rather than detailing operational performance compared to a prior period. Unlike a typical quarterly or annual report, it does not provide updated financial statements or year-over-year comparisons of revenue, margins, or net income. The key information relates to the registration of 9,103,796 shares and the potential $40.4 million from warrant exercises, alongside updates on clinical trial progress and regulatory milestones like the FDA IDE approval.

Key Financial Figures

• $0.0001 — 6 shares of the common stock, par value $0.0001 per share ("Common Stock"), of Anteris
• $40.4 million — ver, we may receive up to approximately $40.4 million in aggregate gross proceeds upon exerci
• $3.85 — rice for our Common Stock on Nasdaq was $3.85 per share. Investing in our Common Stoc
• $1 — were made at the rate of approximately A$1 to $0.650. We make no representation th
• $0.650 — ade at the rate of approximately A$1 to $0.650. We make no representation that the Aus
• $9.9 billion — to ViV procedures is expected to reach $9.9 billion and $2.5 billion, respectively, in 2028
• $2.5 b — s is expected to reach $9.9 billion and $2.5 billion, respectively, in 2028. Our inno
• $6.00 — mon Stock at a public offering price of $6.00 per share. We received net proceeds of
• $80.0 m — per share. We received net proceeds of $80.0 million, after deducting the underwriting
• $4.90 — ing Common Stock Warrant, at a price of $4.90 per share of Common Stock and accompany
• $7.50 — ccompanying CDI Warrant, at a price of A$7.50 per CDI and accompanying CDI Warrant (t
• $11.50 — exercise price of the CDI Warrants is A$11.50 per CDI. As part of the Subscription A

Filing Documents

• ny20059699x1_s1.htm (S-1) — 535KB
• ny20059699x1_ex5-1.htm (EX-5.1) — 12KB
• ny20059699x1_ex21-1.htm (EX-21.1) — 5KB
• ny20059699x1_ex23-1.htm (EX-23.1) — 2KB
• ny20059699x1_ex23-2.htm (EX-23.2) — 2KB
• ny20059699x1_ex107.htm (EX-FILING FEES) — 31KB
• logo_anteris.jpg (GRAPHIC) — 33KB
• ny20059699x1_ex5-1img01.jpg (GRAPHIC) — 2KB
• ny20059699x1_ex23-1img01.jpg (GRAPHIC) — 30KB
• 0001140361-25-043521.txt ( ) — 823KB
• ny20059699x1_ex107_htm.xml (XML) — 14KB

RISK FACTORS

RISK FACTORS 5 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 6

USE OF PROCEEDS

USE OF PROCEEDS 8 MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY 9

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 10 THE PRIVATE PLACEMENT 17 SELLING STOCKHOLDERS 18 PLAN OF DISTRIBUTION 21 LEGAL MATTERS 23 EXPERTS 23 LIMITATION ON INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S LIABILITY 23 WHERE YOU CAN FIND MORE INFORMATION 23 INCORPORATION BY REFERENCE 24 i TABLE OF CONTENTS ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC") using the "shelf" registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, offer and sell, on a resale basis, the shares of Common Stock described in this prospectus in one or more offerings. The Selling Stockholders may use the shelf registration statement to sell up to an aggregate of 9,103,796 shares of Common Stock from time to time through any means described in the section entitled "Plan of Distribution." We will not receive any proceeds from the sale by the Selling Stockholders of the shares of Common Stock offered by them described in this prospectus, except with respect to up to approximately $40.4 million in aggregate gross proceeds upon exercise of the Warrants. A prospectus supplement may also add, update or change information included in this prospectus. Any statement contained in this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in such prospectus supplement modifies or supersedes such statement. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. You should rely only on the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. See "Where You Can Find More Information" and "Information Incorporated by Reference." We and the Sellin

Use of Proceeds

Use of Proceeds We will not receive any of the proceeds from such sales of the shares of our Common Stock by the Selling Stockholders. However, we may receive up to approximately $40.4 million in aggregate gross proceeds upon exercise of the Warrants. We will bear all costs, expenses and fees in connection with the registration of our Common Stock hereunder. The Selling Stockholders will bear all commissions, discounts and certain other limited expenses, if any, attributable to their sales of our Common Stock. Unless we inform you otherwise in a prospectus supplement or free writing prospectus, we expect to use the net proceeds from the exercise of such Warrants primarily for the ongoing development of our DurAVR THV system, the preparation and enrollment of the PARADIGM Trial of DurAVR THV system for treating severe aortic stenosis, and ongoing R&D for v2vmedtech, with the remaining for working capital and other general corporate purposes determined from time to time. Our management will have broad discretion over the use of proceeds from the exercise of the Warrants. Exercise Price of Common Stock Warrants $7.50. Exercise Price of CDI Warrants A$11.50. Listing Our Common Stock is listed on Nasdaq under the symbol "AVR." Our CDIs trade on the ASX under the symbol "AVR." 4 TABLE OF CONTENTS

RISK FACTORS

RISK FACTORS Investing in our Common Stock involves a high degree of r

View Full Filing

View this S-1 filing on SEC EDGAR